7 Sources
[1]
Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials
Isomorphic Labs, the AI drug-discovery platform that was spun out of Google's DeepMind in 2021, has raised $5 billion in a Series C funding round as it seeks to take its drug candidates to clinical trials. The funding was co-led by Greenoaks and Sequoia Capital, with new investor Andreessen
[2]
AI drug developer Isomorphic raises $5 billion in Series C round
Nov 17 (Reuters) - Isomorphic Labs said on Tuesday it has raised $5 billion in a Series C funding round co-led by Greenoaks and Sequoia Capital, as the Alphabet-backed (GOOGL.O), opens new tab AI drug discovery company works to move its first drug candidates into clinical trials. The company,
[3]
Demis Hassabis' AI company raises $5 billion, months after he left as Google DeepMind CEO
* Isomorphic Labs, an artificial intelligence drug discovery startup founded by former Google DeepMind chief Demis Hassabis, has raised $5 billion. * AI labs and investors are funnelling resources and cash into tools looking to use AI to develop new medicines. * Isomorphic's round comes
[4]
Isomorphic Labs raises $5bn in a round led by Sequoia and Greenoaks
Isomorphic Labs did not disclose its valuation. Demis Hassabis told Bloomberg the money will speed its move towards clinical trials, and that it has 'very secure compute pipelines'. Isomorphic Labs, the Alphabet drug discovery company run by Demis Hassabis, has raised $5bn in a Series C round
[5]
Isomorphic Labs raised $5 billion for AI drug discovery
Greenoaks and Sequoia Capital co-led the round as the Alphabet unit works to move its first drug programs toward clinical trials Alphabet $GOOGL's Isomorphic Labs raised $5 billion in a Series C round, the company said on Tuesday, to scale its AI drug design engine and move its first drug
[6]
Alphabet's Isomorphic Labs raises $5B to accelerate drug discovery with AI
Isomorphic Labs Ltd. today announced that it has closed a $5 billion investment led by Greenoaks and Sequoia Capital. The venture capital firms were joined by more than a half-dozen other backers. The group included Isomorphic parent Alphabet Inc., which made a "significant investment." The search
[7]
Isomorphic Labs Limited announced that it has received $5 billion in funding from a group of investors
Isomorphic Labs Limited announced that it has raised $5,000 million in a round of funding co-led by new investors Greenoaks LLC and Sequoia Capital Operations LLC on November 17, 2026. The transaction included participation from new investor Andreessen Horowitz LLC, and several other new investors,
Share
Copy Link
Isomorphic Labs, Alphabet's AI drug-discovery company, raised a $5 billion Series C announced on Tuesday, co-led by Greenoaks and Sequoia Capital with Andreessen Horowitz among the new investors
4
2
3
. It is reportedly one of the largest funding rounds AI drug discovery has drawn this year4
, and the money is meant to push the company's first drug candidates toward clinical trials1
.
Source: Quartz
Every existing investor came back, and Alphabet itself put in more
4
1
7
. No valuation was disclosed, though Bloomberg reported earlier in November that Isomorphic would be valued at roughly $50 billion in the round4
2
1
. It is the company's second giant round in six months, after a $2.1 billion Series B in May led by Thrive Capital1
. Total funding stands at $7.7 billion per Market Screener7
. The wider field is flush too: drug discovery startups have raised a record $23.2 billion this year, according to Dealroom's count, and OpenAI and Anthropic have both moved into the area3
5
.Hassabis said the money will scale the company's IsoDDE drug design engine, fund foundational biology models and push its first therapeutic programs toward clinical trials
3
5
6
. "What we're trying to build is a platform to do hundreds of drugs a year," he told Bloomberg4
. That ambition sits against a current pipeline of more than 20 programs4
5
.
Source: SiliconANGLE
Those programs have produced positive preclinical results in oncology and immunology, in Isomorphic's own work and with partners Eli Lilly, Novartis and Johnson & Johnson
4
1
5
. All of the results so far are preclinical5
. The company also plans to expand beyond small-molecule drugs into biologics and to build the infrastructure for clinical development4
6
. Sequoia partner Konstantine Buhler said his firm invested on the view that Isomorphic has discovered scaling laws for its models, meaning performance keeps improving as compute and data grow4
.In January, Hassabis said the first clinical trials would begin by the end of 2026
4
5
. Asked this month, he declined to give an updated timeline, saying regulatory submissions for the first oncology program are on track and more news will come in 20274
5
. It is the fund's first raise since August, when Hassabis stepped back as Google DeepMind CEO to become DeepMind's chair and Alphabet's chief scientist, keeping the Isomorphic top job4
3
1
. The Nobel laureate also faced a question about chip supply after Jensen Huang's resignation from Nvidia last week. "We've got very secure compute pipelines," he said, noting that Google designs its own AI chips4
.
Source: The Next Web
The $5 billion arrives before any clinical proof exists. No regulator has yet approved a drug designed by AI, according to Bloomberg's reporting
4
. Isomorphic's first trials would be among the first tests of whether an AI-designed molecule can clear that bar, per Bloomberg4
.Related Stories
Summarized by
Navi
09 May 2026•Startups

31 Mar 2025•Business and Economy

13 Feb 2025•Technology
